Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis

Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis

This report is an insightful source for data, analysis and strategic insights into a Omrix Biopharmaceuticals, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

  • Details of development stage by sector and equipment type.
  • Pipeline products grouped by therapy area, development stage and trial phase.
  • Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
  • Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
  • Product updates covering estimated approval dates and estimated launch dates.
  • Descriptions of novel technologies relating to pipeline products of the company.
  • Patents and patent applications covered for the product.
  • News updates on key events relating to the product and its development.

Reasons to buy

  • A single source to fulfill competitor information relating to products in development.
  • Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

  • Access clinical trial information to map trial results and plan targeted marketing activities.
  • Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
  • Identification of potential investment opportunities.
  • Build up knowledge base for potential distribution and marketing partners.
  • Helps avoid patent infringement.
  • Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Company Snapshot
    • 2.1 Key Information
    • 2.2 Company Overview
    • 2.3 Financial Performance
    • 2.4 Industry Outlook In Vitro Diagnostics
  • 3 Business Description
    • 3.1 Business Overview
    • 3.2 Major Products and Services
      • 3.2.1 Overview
  • 4 Competitors
  • 5 Key Employees
  • 6 Key Employee Biographies
  • 7 Company Statement
  • 8 Locations And Subsidiaries
    • 8.1 Head Office
    • 8.2 Other Locations & Subsidiaries
  • 9 Recent Developments
    • 9.1 Financial Announcements
      • 9.1.1 Aug 11, 2008: Omrix Declares 2Q 2008 Results
      • 9.1.2 May 09, 2008: Omrix Declares Q1 2008 Results
      • 9.1.3 Mar 06, 2008: Omrix Declares Q4 2007 Results
      • 9.1.4 Nov 05, 2007: Omrix Declares Q3 2007 Results
      • 9.1.5 Aug 08, 2007: Omrix Declares Q2 2007 Results
      • 9.1.6 May 08, 2007: Omrix Declares Q1 2007 Results
      • 9.1.7 Mar 08, 2007: Omrix Declares Q4 2006 Results
      • 9.1.8 Nov 07, 2006: Omrix Declares Q3 2006 Results
    • 9.2 Corporate Communications
      • 9.2.1 Aug 11, 2008: Omrix Appoints New CFO
      • 9.2.2 May 15, 2008: Omrix Appoints New Chairman And Director
      • 9.2.3 Feb 01, 2008: Omrix Announces Senior Management Changes
      • 9.2.4 Aug 23, 2007: Omrix Appoints CFO
      • 9.2.5 Apr 05, 2007: Omrix Announces CFO Resignation
      • 9.2.6 Jan 19, 2007: Omrix Appoints New Board Members
    • 9.3 Product News
      • 9.3.1 Jul 25, 2008: Omrix Biopharmaceuticals Receives Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For Evicel Liquid Fibrin Sealant
      • 9.3.2 Mar 27, 2008: OMRIX Biopharmaceuticals Announces Initiation And First Patient Enrollment In Phase II Clinical Trial For Fibrin Patch Product Candidate
      • 9.3.3 Mar 17, 2008: OMRIX Biopharmaceuticals Provides Update On Fibrin Patch Product Candidate
      • 9.3.4 Jan 10, 2008: OMRIX Biopharmaceuticals Receives FDA Approval For General Hemostasis In Surgery Indication For EVICEL Liquid Fibrin Sealant (Human)
      • 9.3.5 Apr 03, 2007: Aeris Therapeutics Initiates Phase 2 Trial Of Biologic Lung Volume Reduction
    • 9.4 Product Approvals
      • 9.4.1 Jul 25, 2008: Omrix Biopharmaceuticals Receives Positive Opinion From Committee For Medicinal Products For Human Use (CHMP) For Evicel Liquid Fibrin Sealant
      • 9.4.2 Jan 10, 2008: OMRIX Biopharmaceuticals Receives FDA Approval For General Hemostasis In Surgery Indication For EVICEL Liquid Fibrin Sealant (Human)
    • 9.5 Clinical Trials
      • 9.5.1 Mar 27, 2008: OMRIX Biopharmaceuticals Announces Initiation And First Patient Enrollment In Phase II Clinical Trial For Fibrin Patch Product Candidate
      • 9.5.2 Mar 17, 2008: OMRIX Biopharmaceuticals Provides Update On Fibrin Patch Product Candidate
      • 9.5.3 Apr 03, 2007: Aeris Therapeutics Initiates Phase 2 Trial Of Biologic Lung Volume Reduction
  • 10 Omrix Biopharmaceuticals, Inc. Pipeline Products
    • 10.1 Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis
      • 10.1.1 Omrix Biopharmaceuticals, Inc. Pipeline Products By Equipment Type
      • 10.1.2 Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
      • 10.1.3 Omrix Biopharmaceuticals, Inc. Pipeline Products By Therapy Area
      • 10.1.4 Omrix Biopharmaceuticals, Inc. Pipeline Products By Clinical Trials
      • 10.1.5 Omrix Biopharmaceuticals, Inc. Pipeline Products By News Summary
    • 10.2 Evicel
      • 10.2.1 Product Description
      • 10.2.2 Product Status
      • 10.2.3 Product Milestone
    • 10.3 Evithorm
      • 10.3.1 Product Description
      • 10.3.2 Product Status
    • 10.4 Fibrin Patch
      • 10.4.1 Product Description
      • 10.4.2 Product Status
      • 10.4.3 Clinical Trials
      • 10.4.4 Product Milestone
    • 10.5 Biologic Lung Volume Reduction System
      • 10.5.1 Product Description
      • 10.5.2 Product Status
      • 10.5.3 Clinical Trials
      • 10.5.4 Product Milestone
    • 10.6 Flowable thrombin
      • 10.6.1 Product Description
      • 10.6.2 Product Status
  • 11 Appendix
    • 11.1 Methodology
      • 11.1.1 Coverage
      • 11.1.2 Secondary Research
      • 11.1.3 Primary Research
      • 11.1.4 Expert Panel Validation
    • 11.2 Contact Us
    • 11.3 About Global Markets Direct
    • 11.4 Disclaimer
  • 1 List of Tables
    • Table 1: Omrix Biopharmaceuticals, Inc.,Key Facts
    • Table 2: Omrix Biopharmaceuticals, Inc., Key Employees,
    • Table 3: Omrix Biopharmaceuticals, Inc., Other Locations
    • Table 4: Omrix Biopharmaceuticals, Inc., Subsidiaries
    • Table 5: Omrix Biopharmaceuticals, Inc. Pipeline Products by Equipment Type
    • Table 6: Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
    • Table 7: Omrix Biopharmaceuticals, Inc. Pipeline Products By Therapy Area
    • Table 8: Omrix Biopharmaceuticals, Inc. Pipeline Products By Clinical Trials
    • Table 9: Omrix Biopharmaceuticals, Inc. Pipeline Products By News Summaries
    • 1.2 List of Figures
    • Figure 1: Omrix Biopharmaceuticals, Inc. Pipeline Products By Development Stage
    • Figure 2: Global Markets Direct Methodology
+44 20 8816 8548

Ask a question about Omrix Biopharmaceuticals, Inc. Product Pipeline Analysis

Enter the characters you see in the picture below
Captcha